The deregulation of cGMP signaling in breast tumors is likely due to an overall up-regulation of cGMP-hydrolyzing PDE5, a decrease in intracellular cGMP levels due to an overexpression of MRP5 responsible for cGMP efflux, and the down-regulation of PKG, the main cGMP effector. Here, PDE5A is linked to breast neoplasm.